American Hospital Association responds to changing healthcare landscape with new strategic plan

Matt O'Connor | | Health Exec | Management

The American Hospital Association released a new strategic plan on Tuesday that reflects the changing healthcare landscape and the need to provide more equitable care.

U.S. hospitals have been under intense strain for more than two years as a result of the pandemic, and this 2022-2024 strategic plan reflects near-term priorities and long-term strategies to advance healthcare.

“Recognizing the new environment we are in, the AHA has developed a three year strategic plan that we believe will get us closer to achieving our vision of a just society of healthy communities, where all individuals reach their highest potential for health,” the association said in a special bulletin posted Feb. 8.

Below are the five pillars and goals of the plan.

  1. Provide better care and greater value.
  2. Ensure hospitals and health systems remain financially stable.
  3. Improve public trust and confidence in hospitals and health systems.
  4. Fix near- and short-term workforce and staffing shortages.
  5. Bolster the consumer healthcare experience.

The AHA Board of Trustees approved the plan last month, incorporating input from hospital and health system leadership, along with state, regional and metropolitan association partners.

You can download the entire plan here.

""
Matt O'Connor

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.